The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Chulkova S.V.
N.N. Blokhin National Medical Research Center of Oncology;
Pirogov Russian National Research Medical University
Sholokhova E.N.
N.N. Blokhin National Medical Research Center of Oncology
Poddubnaya I.V.
Russian Medical Academy of Continuous Professional Education
Gladilina I.A.
N.N. Blokhin National Medical Research Center of Oncology;
Pirogov Russian National Research Medical University
Egorova A.V.
Pirogov Russian National Research Medical University
Stilidi I.S.
N.N. Blokhin National Medical Research Center of Oncology;
Pirogov Russian National Research Medical University
Expression of transferrin receptor 1 and β1-integrins correlates with estrogen receptor status and immune infiltration in breast cancer
Journal: Russian Journal of Archive of Pathology. 2024;86(4): 23‑30
Views: 653
Downloaded: 0
To cite this article:
Chulkova SV, Sholokhova EN, Poddubnaya IV, Gladilina IA, Egorova AV, Stilidi IS. Expression of transferrin receptor 1 and β1-integrins correlates with estrogen receptor status and immune infiltration in breast cancer. Russian Journal of Archive of Pathology.
2024;86(4):23‑30. (In Russ.)
https://doi.org/10.17116/patol20248604123
Cancer cells can aberrantly express various markers, including transferrin receptor 1 (CD71) and β1-integrin molecules. Their role in invasion, migration and metastasis has been demonstrated. Determination of their expression in breast cancer (BC) may be an important point to characterize the clinical course of the tumor and prognosis of the disease.
To study of transferrin receptor 1 (CD71) expression by primary breast cancer cells in correlation with tumor cell phenotype.
Determination of BC phenotype: immunohistochemical staining method (immunofluorescence). Antibodies to ER (estrogen receptors), KL-1 (pancytokeratin), CD71 (transferrin receptor), CD29 (β1-integrins). CD45, CD3, CD4, CD8, CD20 infiltration was also evaluated. ZEISS microscope (AXIOSKOP; Germany), method of G.J. Hammerling et al. Statistical processing: IBM-SPSS Statistics v.21.
63% of BC cases had CD71+ phenotype. CD71-mosaic tumors were observed in 14.4%. β1-integrin expression was monomorphic in 51.6% of cases and mosaic in 38.7%. 85% of ER-positive tumors were CD71-positive with a monomorphic type of reaction; p=0.014. Among ER-negative tumors, CD71-negative reactions were 2-fold more frequent and the monomorphic type was less frequent. ER-positive tumors were CD29-positive in 73%; p=0.031. 45.5% of ER+ tumors were CD29-monomorphic. Among ER-negative tumors, the frequency of CD29-monomorphic tumors was 55%. Significant infiltration by CD3+ cells was predominant in CD71-positive tumors; p=0.016. In the CD29-monomorphic phenotype, CD45+ infiltration was 31.3%, and in the mosaic phenotype, 67.1%.
BC aberrantly expresses transferrin receptors, β1-integrins. CD71 expression is associated with ER expression. ER-positive tumors are often monomorphic for CD71. Prominent CD3+ infiltration was present in CD71+ tumors. Expression of β1-integrins correlated with ER+ status and weak immune infiltration.
Keywords:
Authors:
Chulkova S.V.
N.N. Blokhin National Medical Research Center of Oncology;
Pirogov Russian National Research Medical University
Sholokhova E.N.
N.N. Blokhin National Medical Research Center of Oncology
Poddubnaya I.V.
Russian Medical Academy of Continuous Professional Education
Gladilina I.A.
N.N. Blokhin National Medical Research Center of Oncology;
Pirogov Russian National Research Medical University
Egorova A.V.
Pirogov Russian National Research Medical University
Stilidi I.S.
N.N. Blokhin National Medical Research Center of Oncology;
Pirogov Russian National Research Medical University
Received:
25.01.2024
Accepted:
24.04.2024
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.